EVOKE PHARMA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 41 rows in 2025. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2025-12-17: Reporting owner PYSZCZYMUKA GREG; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2025-12-17: Reporting owner PYSZCZYMUKA GREG; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2025-12-17: Reporting owner Smeal Benjamin C.; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2025-12-17: Reporting owner Smeal Benjamin C.; Form 4; Security Stock Option (Right to Buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-12-17 | PYSZCZYMUKA GREG Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,833 0 owned after | $5.26 exercise price | 2025-12-17 | |
| 2025-12-17 | PYSZCZYMUKA GREG Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,155 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | Smeal Benjamin C. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,833 0 owned after | $5.51 exercise price | 2025-12-17 | |
| 2025-12-17 | Smeal Benjamin C. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,125 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −17,291 0 owned after | $5.27 exercise price | 2025-12-17 | |
| 2025-12-17 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −11,000 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,479 0 owned after | $5.41 exercise price | 2025-12-17 | |
| 2025-12-17 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −8,750 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,291 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,218 0 owned after | $5.41 exercise price | 2025-12-17 | |
| 2025-12-17 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,833 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,218 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | Kowieski Mark Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −17,291 0 owned after | $5.27 exercise price | 2025-12-17 | |
| 2025-12-17 | Kowieski Mark Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −13,000 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,187 0 owned after | $5.41 exercise price | 2025-12-17 | |
| 2025-12-17 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,833 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,187 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,218 0 owned after | $5.41 exercise price | 2025-12-17 | |
| 2025-12-17 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,833 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,187 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,250 0 owned after | $5.41 exercise price | 2025-12-17 | |
| 2025-12-17 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,833 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-12-17 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −1,250 0 owned after | $3.45 exercise price | 2025-12-17 | |
| 2025-12-17 | D'Onofrio Matthew J Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −64,840 0 owned after | $5.27 exercise price | 2025-12-17 | |
| 2025-12-17 | D'Onofrio Matthew J Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −70,000 0 owned after | $4.45 exercise price | 2025-12-17 | |
| 2025-05-21 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,187 8,238 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-05-21 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,218 8,269 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-05-21 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,291 11,520 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-05-21 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,250 8,333 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-05-21 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,187 8,207 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-05-21 | Smeal Benjamin C. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,125 6,958 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-05-21 | PYSZCZYMUKA GREG Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,155 6,988 owned after | $3.45 exercise price | 2025-05-22 | |
| 2025-02-20 | PYSZCZYMUKA GREG Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,833 5,833 owned after | $5.26 exercise price | 2025-02-24 | |
| 2025-01-28 | D'Onofrio Matthew J Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +70,000 70,000 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,833 5,833 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,833 5,833 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,833 5,833 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,833 5,833 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,750 8,750 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | Kowieski Mark Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,000 13,000 owned after | $4.45 exercise price | 2025-01-29 | |
| 2025-01-28 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,000 11,000 owned after | $4.45 exercise price | 2025-01-29 |